New advances in genomic technologies now lead the way for understanding and applying this knowledge in personalized, clinical medicine.
Wide-ranging studies of genetic aberrations have identified recurrent genomic abnormalities as potential driving factors underlying a variety of cancers and other diseases.
At PacificDx Testing Services, we support many of these leading-edge molecular and non-molecular technologies for diagnostic biomarker interrogation, drug selection targeting and therapeutic monitoring. These include but are not limited to Next Generation Sequencing (NGS), Enzyme-linked immunosorbent assay (ELISA), Flow Cytometry and Real-Time PCR and Immunohistochemistry (IHC). If you don’t see what you are looking for, please ask — we are a premier high-complexity molecular laboratory with advanced capabilities.
Our Testing Services:
The ibs-smart™ assay serves as a diagnostic aid for IBS-D especially post-infection by providing relevant immunological information about antibodies to cytothelial distending toxin B (CdtB) and vinculin.
Methodology: Enzyme linked immunoabsorbant (ELISA) assay is used to assess circulating antibody levels of CdtB and vinculin in patients exhibiting symptoms of IBS. The assay does not provide exclusive diagnosis of IBS. Results should be interpreted in the context of the patient’s clinical and laboratory findings.
For Patients: For information on obtaining the test, please visit: ibs-smart.com
Multiplex testing of squamous and non-squamous NSC lung cancer tissue allows interrogation of a maximum number of biomarkers from minimal tumor tissue.
Methodology: Sequencing of uniquely indexed target enriched libraries is performed using an Illumina MiSeq instrument with bioinformatics analysis through an assay specific pipeline. This assay only reports the following variants in the following genes:
|MET:||Reported areas include Point mutations and Ins/Del|
|AXL:||Chromosomal rearrangements including but not limited to MBIP-AXL (or alternative) and amplifications|
|KRAS:||Point mutations involving codon 12, 13, 61|
|EGFR:||Point mutations and Ins/Del: L858R, T790M, G719A/D/S, S768I, L861Q/R, Exon 20ins, Exon 19del|
|ALK:||Rearrangements including but not limited to EML4-ALK|
|BRAF:||Point mutations: V600E, V600D, V600K, V600R, G464V, G466E, G466E, G466A, G469V, G469L, G469R, G469A, N581S, N581T, D594N, D594H, D594G|
|ROS:||Chromosomal rearrangements including but not limited to CD74-ROS, EZR-ROS, SDC4-ROS, SLC34A2-ROS, TPM3-ROS|
|RET:||Point mutations including, but not limited to, C630R, C634R/W/Y, M918T, Chromosomal rearrangements including but not limited to KIF5B-RET or CCDC6|
|NTRK1:||Chromosomal rearrangements including but not limited to MPRIP-NTRK1, CD74-NTRK1, TPM3-NTRK1, TFG-NTRK1|
|NTRK2:||Point mutations: R715G, M713I, R734C|
The CD8 antibody reacts with the 32 kDa CD8 protein and stains cells with cytotoxic activity including cortical thymocytes, cytotoxic/suppressor T-cells and a subset of natural killer (NK) cells.
Methodology: PacificDx performs CD8 using the Biocare mouse monoclonal antibody [C8/144B] for qualitative identification of CD8 protein by IHC in formalin fixed paraffin embedded (FFPE) tissue.
Overexpression of MCL-1 leads to resistance to programmed cell death in acute myelogenous leukemia (AML) and other cancers. Inhibition of the MCL-1 pathway in this subset of MCL-1 dependent AML patients results in improved sensitivity to chemotherapy.
Methodology: The MCL-1 dependency priming assay uses flow cytometry to measure MCL-1 dependency of bone marrow blasts in patients with AML.